CGEM Live signals | Maximize Profits with Getagraph.com

SELL 131607 min ago

@ $17.99

Issued: 14 Feb 2024 @ 15:07

Return: 48.53%

Previous signal: Feb 14 - 14:44

Previous signal: Buy

Return: 1.47 %

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 16:00):

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States...

Stats
Today's Volume	706 986
Average Volume	737 844
Market Cap	1.15B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.980 ) 2024-06-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.24
ATR14	$0.0440 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-06	Michaelson Jennifer	Buy	50 000	Common Stock
2024-05-06	Michaelson Jennifer	Sell	37 723	Common Stock
2024-05-06	Michaelson Jennifer	Sell	50 000	Stock Option (Right to Buy)
2024-05-07	Michaelson Jennifer	Buy	5 606	Common Stock
2024-05-07	Michaelson Jennifer	Sell	5 606	Stock Option (Right to Buy)

INSIDER POWER
54.92
Last 99 transactions
Buy: 2 506 121 \| Sell: 594 695

Volume Correlation

Long: -0.30 (neutral)

Short: 0.33 (neutral)

Signal:(45.681) Neutral

Cullinan Oncology, LLC Correlation

10 Most Positive Correlations
BNIXU	0.96
SGEN	0.914
ATVI	0.879
STAY	0.876
VLATU	0.874
TIOAU	0.872
FTIV	0.871
RADI	0.87
NTIC	0.868
FOCS	0.867

10 Most Negative Correlations
RMRM	-0.924
NMTR	-0.915
TLGT	-0.887
CETX	-0.882
EVOK	-0.875
GLBS	-0.874
SBAC	-0.872
IDBA	-0.871
BFI	-0.869
WINT	-0.869

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cullinan Oncology, LLC Correlation - Currency/Commodity

0.60
( weak )

0.63
( weak )

0.00
( neutral )

0.32
( neutral )

0.41
( neutral )

-0.21
( neutral )

Cullinan Oncology, LLC Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-310 000 (0.00 %)
EPS:	$-3.69

FY	2023
Revenue:	$0
Gross Profit:	$-310 000 (0.00 %)
EPS:	$-3.69

FY	2022
Revenue:	$0
Gross Profit:	$-93 000.00 (0.00 %)
EPS:	$2.46

FY	2021
Revenue:	$18 943.00
Gross Profit:	$18 943.00 (100.00 %)
EPS:	$-0.00157

Financial Reports:

No articles found.

Cullinan Oncology, LLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cullinan Oncology, LLC

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.